Our numbers, however, are much higher than the US data—they report initiation rates of 2.5% for SGLT-2 inhibitors, 3.7% for DPP-4 inhibitors, 2.31% for GLP-1 receptor analogues, 4% for insulin, and 5.5% for sulfonylureas in T2DM-CKD [38]. The gene discussed is SLC5A2; the disease is chronic kidney disease.